Symposium to address how new AI-powered analytic and workflow
solutions for clinical and biopharma markets are advancing
data-driven medicine
Symposium encapsulates SOPHiA GENETICS and GE Healthcare
alliance to provide joint solutions and multimodal analytics to
healthcare providers and biopharma companies
CHICAGO, Nov. 29, 2021 /PRNewswire/ -- SOPHiA
GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling
and knowledge sharing platform that advances data-driven
medicine, announced today they will be hosting a joint
symposium with GE Healthcare titled "Advancing data-driven
medicine: unlocking the potential of multimodal digital health data
sets by combining longitudinal radiomics and genomics data with
AI-powered analytics," during the Radiological Society of
North America 2021 Annual Meeting
at 9:30am CT on Wednesday, December
1. The symposium will reflect on recent advances in
multimodal clinical research and the role of the radiologist in
this healthcare revolution.
This symposium follows the recent announcement of the signed
Master Alliance Agreement and July
2021 letter of intent pursuant to which SOPHiA GENETICS and
GE Healthcare will be collaborating on opportunities in the
healthcare market, including various initiatives and projects in
the fields of digital oncology and radiogenomic analysis. The
companies will initially work together on the creation of
infrastructure to integrate data between GE's Edison platform and
the SOPHiA DDM™ platform, as well as co-marketing and pilot site
recruitment across oncology and radiogenomics.
"We are thrilled about our alliance with GE Healthcare to
further accelerate the adoption of our platform worldwide," said
Jurgi Camblong, co-founder and CEO, SOPHiA
GENETICS. "This alliance is a significant catalyst for
SOPHiA GENETICS and will help us fast-track innovation, more
quickly increase the size and scale of our network, and offer a
greater expansion of capabilities to help clinicians and
researchers ensure cancer patients worldwide will be able to
receive equal access to better diagnosis and treatments."
"This collaboration with SOPHiA GENETICS is a further step
towards GE Healthcare's vision of making precision health - more
efficient and personalized care - a reality," said
Jan Makela, President & CEO at
GE Healthcare Imaging. "Integrating genomics data and artificial
intelligence into oncology workflow solutions, beginning with the
integration of data from GE's Edison platform and the SOPHiA DDM
platform will further our goal to help clinicians and researchers
break down the data silos across instruments."
About SOPHiA GENETICS:
SOPHiA GENETICS is a healthcare technology company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
more than 780 hospital, laboratory, and biopharma institutions
globally.
More info: SOPHiAGENETICS.COM;
follow @SOPHiAGENETICS on Twitter.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenertics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this document speak
only as of the date of this press release. We expressly disclaim
any obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg